PALO ALTO, Calif., Dec. 22 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of shares of its common stock.
Alexza Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions.
The underwriters of the offering will be Piper Jaffray & Co. and Pacific Growth Equities, LLC, acting as joint book running managers, and RBC Capital Markets and JMP Securities, acting as co-managers. The number of shares to be offered and the price range for the offering have not been determined.
The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from the prospectus department of either Piper Jaffray & Co. (800 Nicollet Mall, Suite 800, Attention: Equity Capital Markets, Minneapolis, MN 55402, by phone at 612.303.6220 or by fax at 612.303.1070), Pacific Growth Equities, LLC (c/o Prospectus Department, One Bush Street, Suite 1700, San Francisco, CA 94104, by phone at 415.274.6819 or by fax at 415.274.6887), RBC Capital Markets (One Liberty Plaza, New York, NY 10006, by phone at 212.858.7000 or by fax at 212.428.6200) or JMP Securities (600 Montgomery Street, Suite 1100, San Francisco, CA 94111, by phone at 415.835.8900 or by fax at 415.835.8910).
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Source: Alexza Pharmaceuticals, Inc.
